Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 242 participants.
Also called NCT04274049
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 242 participants
- Registry
-
NCT04274049
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04274049. Randomized; quadruple masking; primary purpose treatment. Start 2019-08-28 (actual); primary completion 2023-12-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)
- Condition
- Arterial Occlusive Disease
- Condition
- Ischemia
- Condition
- Ulcers
- Condition
- Peripheral Vascular Disease
- Intervention (Genetic)
- NL003
- Intervention (Other)
- Normal Saline
- Lead sponsor
- Beijing Northland Biotech. Co., Ltd.
Record details
- Record id
cardio:ct-nct04274049- Content hash
665b0e62d35360940ab9c887c74e33c32bd12ce89b98fd21596e8d268c594892